Helix BioPharma Announces Voting Results from Annual General and Special Meeting
Toronto, Ontario — January 30, 2026 — Leads & Copy — Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) announced the voting results from its Annual General and Special Meeting of Shareholders held on Friday, January 30, 2026.
Shareholders overwhelmingly approved all items of business, with 61,885,815 common shares voted, representing 81.03% of Helix’s total issued and outstanding shares.
The four director nominees listed in the Management Information Circular dated December 15, 2025, were re-elected. Jacek Antas received 61,885,252 votes in favor (99.99%), Jerzy Leszczynski received 61,885,812 votes in favor (99.99%), Janusz Grabski received 61,885,792 votes in favor (99.99%), and Malgorzata Laube received 61,885,792 votes in favor (99.99%).
The appointment of Clearhouse LLP as auditor until the next annual general meeting, with remuneration determined by the directors, was approved with 99.99% of the votes cast in favor.
The resolution to amend the articles of the Company to consolidate issued and outstanding common shares, with a consolidation ratio selected by the directors of up to five pre-consolidation common shares for one post-consolidation common share, was approved with 99.99% of the votes cast in favor. The Board is authorized to determine the final consolidation ratio at its sole discretion.
A report on all items of business voted at the Meeting will be filed on SEDAR+ at www.sedarplus.com.
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing novel therapies for hard-to-treat cancers. Its pipeline is spearheaded by the Tumour Defence Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of common, hard-to-treat solid tumors. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC), with novel strategically designed bi-specific ADCs targeting CEACAM6 in discovery.
Helix is listed on the TSX under the symbol “HBP”, on OTC PINK under the symbol “HBPCD” and on FWB under the symbol “HBP0”.
Source: Helix BioPharma Corp.
Share this story:
